ODP350 Safety and Efficacy of Tesomet over 48 Weeks of Treatment: Results From a 24-Week Phase 2, Randomized, Double-Blind Study With 24 Week Open-Label Extension in Adults With Hypothalamic Obesity

OBJECTIVE: To assess the safety and efficacy of Tesomet (tesofensine plus metoprolol) in adults with hypothalamic obesity, a rare disease with no approved therapy. RESEARCH DESIGN AND METHODS: Twenty-one adults with hypothalamic obesity (16 females, 5 males) were randomized to Tesomet (0.5 mg tesofe...

Descripción completa

Detalles Bibliográficos
Autores principales: Klose, Marianne, Huynh, Kim, Krogsgaard, Kim, Drejer, Jørgen, Pharm, Dr, Byberg, Sarah, Madsbad, Sten, Magkos, Faidon, Researcher, Senior, Aharaz, Abdellatif, Edsberg, Berit, Tfelt, Jacob, Astrup, Arne, Feldt-Rasmussen, Ulla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625380/
http://dx.doi.org/10.1210/jendso/bvac150.1059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625380/
http://dx.doi.org/10.1210/jendso/bvac150.1059

Ejemplares similares